HIV virus (yellow) infecting a human cell. Credit: ZEISS Microscopy.

Janssen Pharmaceutical Companies and ViiV Healthcare UK have received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorisation of Juluca to treat HIV-1 infection.

Juluca is a single-pill, two-drug regimen consisting of 50mg of ViiV Healthcare’s dolutegravir and 25mg of rilpivirine manufactured by Janssen.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Dolutegravir is an integrase strand transfer inhibitor, while rilpivirine blocks non-nucleoside reverse transcriptase enzymes.

The recommendation covers the use of the drug in adults who are virologically suppressed and have been on a stable antiretroviral regimen for a minimum of six months and do not have a history of virological failure.

Janssen Research & Development global head Mathai Mammen said: “We are delighted to be one step closer to bringing Juluca to people living with HIV in Europe.

“This is an important milestone towards continuing to grow our portfolio of treatment options, to help meet the diverse and individual needs of people living with HIV.”

“Building on our 25-year commitment to make HIV history, this is an important milestone towards continuing to grow our portfolio of treatment options, to help meet the diverse and individual needs of people living with HIV.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The CHMP positive opinion comes after a review of findings from two Phase III clinical trials and a bioequivalence study.

Results from both trials demonstrated the non-inferiority of the dolutegravir/rilpivirine regimen in sustained virologic suppression through 48 weeks, compared to three and four drug combinations.

The dolutegravir and rilpivirine regimen was approved by the US Food and Drug Administration in November 2017 for the treatment of adults with HIV-1.

ViiV Healthcare UK has also submitted regulatory marketing applications for the regimen in Canada, Australia and Switzerland.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact